Combined hormonal contraceptives: Is it time to reassess their role in migraine?

Headache

Volumn 52, Issue 4, 2012, Pages 648-660

  Calhoun, Anne ^a,b  

^a From the Carolina Headache Institute   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

estrogen; menstrual migraine; migraine; migraine with aura; oral contraceptive; stroke

Indexed keywords

CHLORMADINONE ACETATE; CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DROSPIRENONE; ELCOMETRINE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETYNODIOL DIACETATE; GESTAGEN; GESTODENE; LEVONORGESTREL; LYNESTRENOL; MESTRANOL; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETYNODREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; TANAPROGET; TRIMEGESTONE;

DEMOGRAPHY; DRUG FORMULATION; DRUG MEGADOSE; EUROPE; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; INFORMATION RETRIEVAL; MEDICAL RESEARCH; MENSTRUAL MIGRAINE; META ANALYSIS; METABOLIC DISORDER; MIGRAINE; NETHERLANDS; OBSTETRICS; PILL; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK BENEFIT ANALYSIS; STROKE; VAGINA RING; VEIN THROMBOSIS;

CONTRACEPTIVES, ORAL, HORMONAL; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIGRAINE DISORDERS; RISK FACTORS; STROKE;

EID: 84859699885     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.02051.x     Document Type: Review

References (72)

1. Somerville BW,. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology. 1975; 25: 239-244.
2. Speroff LD, Philip D,. "Oral Contraception." A Clinical Guide for Contraception, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
3. Mosher WD, Jones J,. Use of contraception in the United States: 1982-2008. Vital Health Stat 23. 2010; 29: 1-44.
4. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB,. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008; 28: 1170-1178.
5. Bast RC Jr, Brewer M, Zou C, et al,. Prevention and early detection of ovarian cancer: Mission impossible? Recent Results Cancer Res. 2007; 174: 91-100.
6. Tietjen GE, Conway A, Utley C, Gunning WT, Herial NA,. Migraine is associated with menorrhagia and endometriosis. Headache. 2006; 46: 422-428.
7. Huber JC, Bentz EK, Ott J, Tempfer CB,. Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacother. 2008; 9: 2317-2325.
8. Vessey M, Yeates D, Flynn S,. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010; 82: 221-229.
9. Calhoun A, Ford S,. Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache. 2008; 48: 1186-1193.
10. Granella F, Sances G, Allais G, et al,. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004; 24: 707-716.
11. MacGregor EA, Hackshaw A,. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004; 63: 351-353.
12. Calhoun AH,. A novel specific prophylaxis for menstrual-associated migraine. South Med J. 2004; 97: 819-822.
13. Sulak P, Willis S, Kuehl T, Coffee A, Clark J,. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache. 2007; 47: 27-37.
14. Martin VT, Behbehani M,. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis-part I. Headache. 2006; 46: 3-23.
15. Martin VT, Behbehani M,. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis-part 2. Headache. 2006; 46: 365-386.
16. Hellstrom B, Anderberg UM,. Pain perception across the menstrual cycle phases in women with chronic pain. Percept Mot Skills. 2003; 96: 201-211.
17. D'Amico JF, Greendale GA, Lu JK, Judd HL,. Induction of hypothalamic opioid activity with transdermal estradiol administration in postmenopausal women. Fertil Steril. 1991; 55: 754-758.
18. Krause DN, Duckles SP, Pelligrino DA,. Influence of sex steroid hormones on cerebrovascular function. J Appl Physiol. 2006; 101: 1252-1261.
19. Elliott D,. Migraine and stroke: Current perspectives. Neurol Res. 2008; 30: 801-812.
20. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ,. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000; 95: 261-266.
21. Kawano H, Motoyama T, Ohgushi M, Kugiyama K, Ogawa H, Yasue H,. Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina. Ann Intern Med. 2001; 135: 977-981.
22. Choo WK,. Menstruation angina: A case report. J Med Case Reports. 2009; 3: 6618.
23. Lomicek M, Proks V, Presl J,. [Coronary heart disease with a marked vasospastic component associated with the menstrual cycle and its treatment]. Vnitr Lek. 1995; 41: 710-712.
24. Lloyd GW, Patel NR, McGing E, Cooper AF, Brennand-Roper D, Jackson G,. Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease? Heart. 2000; 84: 189-192.
25. Somerville BW,. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972; 22: 355-365.
26. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A,. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006; 67: 2154-2158.
27. Calhoun A,. Four hypotheses for understanding menstrual migraine. Female Patient. 2004; 29: 38-44.
28. Magos AL, Zilkha KJ, Studd JW,. Treatment of menstrual migraine by oestradiol implants. J Neurol Neurosurg Psychiatry. 1983; 46: 1044-1046.
29. Murray SC, Muse KN,. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy. Fertil Steril. 1997; 67: 390-393.
30. Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M,. Menstrual migraine: A double-blind trial of percutaneous estradiol. Gynecol Endocrinol. 1988; 2: 113-120.
31. de Lignieres B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG,. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed). 1986; 293: 1540.
32. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A,. Prevention of menstrual attacks of migraine: A double-blind placebo-controlled crossover study. Neurology. 2006; 67: 2159-2163.
33. Pradalier A, Vincent D, Beaulieu PH, et al,. Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In:, Rose FC, ed. New Advances in Headache Research. London: Smith-Gordon; 1994: 129-132.
34. Calhoun A, Ford S, Pruitt A,. Extended-cycle use of a ring contraceptive may reduce frequency of migraine aura. In: American Headache Society Annual Scientific Meeting. Washington, DC: 2011.
35. Melhado E, Maciel JA Jr, Guerreiro CA,. Headaches during pregnancy in women with a prior history of menstrual headaches. Arq Neuropsiquiatr. 2005; 63: 934-940.
36. Calhoun A,. Women's issues in headache. In:, Loder E, ed. Headache. Philadelphia, PA: American College of Physicians; 2004: 157-177.
37. Ryan RE,. A controlled study of the effect of oral contraceptives on migraine. Headache. 1978; 17: 250-251.
38. Vessey M, Mant D, Smith A, Yeates D,. Oral contraceptives and venous thromboembolism: Findings in a large prospective study. Br Med J (Clin Res Ed). 1986; 292: 526.
39. Oral contraceptives and stroke in young women. Associated risk factors. JAMA. 1975; 231: 718-722.
40. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study. Lancet. 1996; 348: 498-505.
41. Lidegaard O, Kreiner S,. Contraceptives and cerebral thrombosis: A five-year national case-control study. Contraception. 2002; 65: 197-205.
42. Carolei A, Maeini C,. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996; 335: 1767-1768.
43. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK,. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996; 335: 8-15.
44. Schwartz SM, Petitti DB, Siscovick DS, et al,. Stroke and use of low-dose oral contraceptives in young women: A pooled analysis of two US studies. Stroke. 1998; 29: 2277-2284.
45. Chang L, Donaghy M, Poulter N,. Migraine and stroke in young women: Case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ. 1999; 318: 13-18.
46. Kemmeren JM, Tanis BC, van den Bosch MA, et al,. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke. 2002; 33: 1202-1208.
47. Siritho S, Thrift AG, McNeil JJ, You RX, Davis SM, Donnan GA,. Risk of ischemic stroke among users of the oral contraceptive pill: The Melbourne Risk Factor Study (MERFS) Group. Stroke. 2003; 34: 1575-1580.
48. Nightingale AL, Farmer RD,. Ischemic stroke in young women: A nested case-control study using the UK General Practice Research Database. Stroke. 2004; 35: 1574-1578.
49. Mant J, Painter R, Vessey M,. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: An updated analysis of a cohort study. Br J Obstet Gynaecol. 1998; 105: 890-896.
50. Fruzzetti F,. Hemostatic effects of smoking and oral contraceptive use. Am J Obstet Gynecol. 1999; 180: S369-S374.
51. Chan WS, Ray J, Wai EK, et al,. Risk of stroke in women exposed to low-dose oral contraceptives: A critical evaluation of the evidence. Arch Intern Med. 2004; 164: 741-747.
52. Heinemann LA, Lewis MA, Thorogood M, Spitzer WO, Guggenmoos-Holzmann I, Bruppacher R,. Case-control study of oral contraceptives and risk of thromboembolic stroke: Results from the International Study on Oral Contraceptives and Health of Young Women. BMJ. 1997; 315: 1502-1504.
53. Kaplan B,. Desogestrel, norgestimate, and gestodene: The newer progestins. Ann Pharmacother. 1995; 29: 736-742.
54. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995; 346: 1582-1588.
55. Shapiro S,. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric. 2008; 11: 355-363.
56. Poulter NR, Chang CL, Farley TM, Marmot MG, Meirik O,. Effect on stroke of different progestogens in low oestrogen dose oral contraceptives. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1999; 354: 301-302.
57. Donaghy M, Chang CL, Poulter N,. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry. 2002; 73: 747-750.
58. Gudmundsson LS, Scher AI, Aspelund T, et al,. Migraine with aura and risk of cardiovascular and all cause mortality in men and women: Prospective cohort study. BMJ. 2010; 341: c3966.
59. Kurth T, Slomke MA, Kase CS, et al,. Migraine, headache, and the risk of stroke in women: A prospective study. Neurology. 2005; 64: 1020-1026.
60. Lee ST, Chu K, Jung KH, et al,. Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology. 2008; 70: 1510-1517.
61. Kunz GA, Liang G, Cuculi F, et al,. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J. 2006; 152: 190-195.
62. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE,. Migraine and risk of cardiovascular disease in women. JAMA. 2006; 296: 283-291.
63. Pezzini A, Del Zotto E, Giossi A, Volonghi I, Grassi M, Padovani A,. The migraine-ischemic stroke connection: Potential pathogenic mechanisms. Curr Mol Med. 2009; 9: 215-226.
64. MacGregor EA,. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004; 3: 354-361.
65. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006; 107: 1453-1472.
66. MacClellan LR, Giles W, Cole J, et al,. Probable migraine with visual aura and risk of ischemic stroke: The stroke prevention in young women study. Stroke. 2007; 38: 2438-2445.
67. Etminan M, Takkouche B, Isorna FC, Samii A,. Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. BMJ. 2005; 330: 63.
68. Schwaag S, Nabavi DG, Frese A, Husstedt IW, Evers S,. The association between migraine and juvenile stroke: A case-control study. Headache. 2003; 43: 90-95.
69. Ulrich V, Gervil M, Fenger K, Olesen J, Russell MB,. The prevalence and characteristics of migraine in twins from the general population. Headache. 1999; 39: 173-180.
70. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al,. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995; 310: 830-833.
71. Spannagl M, Heinemann LA, Schramm W,. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur J Contracept Reprod Health Care. 2000; 5: 105-112.
72. Price DT, Ridker PM,. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective. Ann Intern Med. 1997; 127: 895-903.